A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Plain-language summary
This trial is testing TLN-254 (an investigational oral agent) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 4 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
TLN-254 (DRUG): TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation. | TLN-254 (DRUG): TLN-254 will be administered orally at a specified dose on specified days.
TLN-254, TLN-254
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details